Multiplexed immunoassay-based serum cytokine profiling for potential prognosis predictors in patients with metastatic breast cancer
Multiplexed immunoassay-based serum cytokine profiling for potential prognosis predictors in patients with metastatic breast cancer
复制标题
基于多重免疫分析的血清细胞因子分析作为转移性乳腺癌患者潜在的预后预测因子
DOI：
10.21037/tcr.2018.11.29
复制
发表时间：
2018-12-01
影响因子：
0.9
通讯作者：
Ren, Jun
中科院分区：
文献类型：
--
作者：
Huang, Hongyan;Zhang, Yanbin;Ren, Jun
背景资料：虽然患有转移性乳腺癌（MBC）的患者经历了相当宽的生存范围，但用于其预后的可靠生物标志物仍然未知。本研究试图分析血清细胞因子的候选者，可以潜在地用于预测MBC patients.Methods的预后：通过使用Procartavin多重免疫分析，共45种细胞因子测定血清中从18 MBC patients.Results：33种类型的细胞因子是交叉检测超过50%的患者，因此是可以接受的进一步分析。单因素分析发现10种血清细胞因子与MBC患者死亡显著相关。其中白细胞介素8（IL-8）、成纤维细胞生长因子2（FGF 2）、肝细胞生长因子（HGF）和VEGF-A已被报道，而神经生长因子β（NGF-beta）、干扰素γ（IFN-γ）、IP-10、IL-18、MCP-1和MIP-1 β等6种细胞因子是首次被鉴定为MBC死亡相关的血清因子。这些细胞因子的鉴定将有助于开发新的MBC血清生物标志物，有利于多重血清细胞因子分析，这是预测MBC患者结局的一种有前途的方法。
Background: Although the patients suffering from metastatic breast cancer (MBC) have experienced considerably wide survival ranges, reliable biomarkers for its prognosis have remained unidentified. This study attempted to profile the serum cytokine candidates that could potentially be used to predict the prognosis of MBC patients.Methods: By using the ProcartaPlex Multiplex Immunoassay, a total of 45 cytokines were assayed in sera from 18 MBC patients before any treatment.Results: Thirty-three types of cytokines were cross-detectable in more than 50% of the patients and thus were acceptable for a further analysis. Univariate analysis uncovered 10 sera cytokines significantly associated with MBC patient death. Among them, interleukin 8 (IL-8), fibroblast growth factor (FGF2), hepatocyte growth factor (HGF) and VEGF-A were reported, and 6 cytokines which included NGF-beta, IFN-gamma, IP-10, IL-18, MCP-1 and MIP-1 beta were identified for the first time as MBC death-correlated serum factors.Conclusions: Identification of these cytokines would facilitate developing novel serum biomarkers for MBC, favoring multiplexed serum cytokine profiling a promising method in predicting the outcome of MBC patients.